Bone phenotypes in multiple endocrine neoplasia type 1: survey on the MEN1 Florentine database.
bone modeling
bone tissue
bone turnover
mineral metabolism
multiple endocrine neoplasia type 1 (MEN1)
osteoporosis
Journal
Endocrine connections
ISSN: 2049-3614
Titre abrégé: Endocr Connect
Pays: England
ID NLM: 101598413
Informations de publication
Date de publication:
11 May 2022
11 May 2022
Historique:
received:
11
03
2022
accepted:
23
03
2022
pubmed:
25
3
2022
medline:
25
3
2022
entrez:
24
3
2022
Statut:
epublish
Résumé
Multiple endocrine neoplasia type 1 (MEN1) is a rare, inherited cancer syndrome characterized by the development of multiple endocrine and non-endocrine tumors. MEN1 patients show a reduction of bone mass and a higher prevalence of early onset osteoporosis, compared to healthy population of the same age, gender, and ethnicity. During the monitoring and follow-up of MEN1 patients, the attention of clinicians is primarily focused on the diagnosis and therapy of tumors, while the assessment of bone health and mineral metabolism is, in many cases, marginally considered. In this study, we retrospectively analyzed bone and mineral metabolism features in a series of MEN1 patients from the MEN1 Florentine database. Biochemical markers of bone and mineral metabolism and densitometric parameters of bone mass were retrieved from the database and were analyzed based on age ranges and genders of patients and presence/absence of the three main MEN1-related endocrine tumor types. Our evaluation confirmed that patients with a MEN1 diagnosis have a high prevalence of earlyonset osteopenia and osteoporosis, in association with levels of serum and urinary markers of bone turnover higher than the normal reference values, regardless of their different MEN1 tumors. Fifty percent of patients younger than 26 years manifested osteopenia and 8.3% had osteoporosis, in at least one of the measured bone sites. These data suggest the importance of including biochemical and instrumental monitoring of bone metabolism and bone mass in the routine medical evaluation and follow-up of MEN1 patients and MEN1 carriers as important clinical aspects in the management of the syndrome.
Identifiants
pubmed: 35324455
doi: 10.1530/EC-21-0456
pii: e210456
pmc: PMC9175581
doi:
pii:
Types de publication
Journal Article
Langues
eng
Références
Endocrine. 2017 Nov;58(2):349-359
pubmed: 28132167
Nutrients. 2020 Apr 08;12(4):
pubmed: 32276412
J Biol Chem. 2015 Feb 13;290(7):3910-24
pubmed: 25538250
J Clin Endocrinol Metab. 2018 Nov 1;103(11):3993-4004
pubmed: 30060226
Osteoporos Int. 2020 Jan;31(1):165-173
pubmed: 31642976
Arch Surg. 1999 Oct;134(10):1119-23
pubmed: 10522858
J Cell Biochem. 2008 Mar 1;103(4):1037-45
pubmed: 18240141
Clin Endocrinol (Oxf). 2010 Apr;72(4):462-8
pubmed: 19650788
Front Endocrinol (Lausanne). 2019 Jun 11;10:339
pubmed: 31263451
Cells. 2021 Jul 26;10(8):
pubmed: 34440663
Indian J Endocrinol Metab. 2018 Nov-Dec;22(6):766-769
pubmed: 30766815
Cell. 1999 Jan 8;96(1):143-52
pubmed: 9989505
Int J Mol Sci. 2021 Apr 14;22(8):
pubmed: 33919851
J Bone Miner Res. 2010 Nov;25(11):2382-91
pubmed: 20499354
Am J Psychiatry. 2003 Sep;160(9):1618-20
pubmed: 12944336
J Clin Endocrinol Metab. 2012 Sep;97(9):2990-3011
pubmed: 22723327
J Bone Miner Res. 2009 Aug;24(8):1404-10
pubmed: 19309299
J Endocrinol Invest. 2012 Jun;35(6):573-9
pubmed: 21791969
Orphanet J Rare Dis. 2018 Nov 14;13(1):205
pubmed: 30428914